Study of Omalizumab as Adjuvant Therapy in Chemotherapy Desensitization

Summary

This research study is evaluating a drug called omalizumab (brand name 'Xolair') as a potential treatment to be used in conjunction with drug desensitization to prevent reactions from recurring and allowing the participant to be treated with the chemotherapy the participant's oncologist prefers to give.

Timeline

Start

2014-07

Primary completion

2017-12

Completion

2017-12

Drugs

Indications